- Home
- ASMB vs SRBK Comparison
ASMB vs SRBK Comparison
Compare ASMB & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- SRBK
- Stock Information
- Founded
- ASMB 2005
- SRBK 1887
- Country
- ASMB United States
- SRBK United States
- Employees
- ASMB N/A
- SRBK N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- SRBK
- Sector
- ASMB Health Care
- SRBK
- Exchange
- ASMB Nasdaq
- SRBK Nasdaq
- Market Cap
- ASMB 141.8M
- SRBK 117.4M
- IPO Year
- ASMB 2010
- SRBK N/A
- Fundamental
- Price
- ASMB $18.86
- SRBK $14.03
- Analyst Decision
- ASMB Strong Buy
- SRBK
- Analyst Count
- ASMB 3
- SRBK 0
- Target Price
- ASMB $33.00
- SRBK N/A
- AVG Volume (30 Days)
- ASMB 29.0K
- SRBK 47.9K
- Earning Date
- ASMB 08-15-2025
- SRBK 07-31-2025
- Dividend Yield
- ASMB N/A
- SRBK 1.42%
- EPS Growth
- ASMB N/A
- SRBK N/A
- EPS
- ASMB N/A
- SRBK 0.44
- Revenue
- ASMB $32,154,000.00
- SRBK $31,833,000.00
- Revenue This Year
- ASMB $0.04
- SRBK N/A
- Revenue Next Year
- ASMB N/A
- SRBK N/A
- P/E Ratio
- ASMB N/A
- SRBK $31.89
- Revenue Growth
- ASMB 148.33
- SRBK 39.53
- 52 Week Low
- ASMB $7.75
- SRBK $9.50
- 52 Week High
- ASMB $19.93
- SRBK $14.96
- Technical
- Relative Strength Index (RSI)
- ASMB 55.48
- SRBK 50.34
- Support Level
- ASMB $16.90
- SRBK $13.55
- Resistance Level
- ASMB $19.43
- SRBK $14.14
- Average True Range (ATR)
- ASMB 1.05
- SRBK 0.27
- MACD
- ASMB -0.09
- SRBK -0.10
- Stochastic Oscillator
- ASMB 75.38
- SRBK 43.44
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.